Pharma Excipients
Pellet
Influence of In Situ Calcium Pectinate Coating on Metoprolol Tartrate Pellets for Controlled Release…
In situ calcium pectinate-coated pellets were proposed by applying an alternate coating method to drug-layered pellets to achieve colon-specific drug delivery. Solution layering of metroprolol tartrate, a water-soluble model drug, on inert core pellets was achieved using a centrifugal granulator…
Read More...
Read More...
Quality aspects in the development of pelletized dosage forms
The aim of this work was to identify and collate the major common challenges that arise during pellet development. These challenges focus on aspects right from raw material properties until the final drying process of the pelletization. The challenges associated with the particle size of drug and…
Read More...
Read More...
Integrated Purification and Formulation of an Active Pharmaceutical Ingredient via Agitated Bed…
Integrated API and drug product processing enable molecules with high clinical efficacy but poor physicochemical characteristics to be commercialized by direct co-processing with excipients to produce advanced multicomponent intermediates. Furthermore, developing isolation-free frameworks would…
Read More...
Read More...
Novel preparation approach with a 2-step process for spherical particles with high drug loading and…
A novel approach for preparing drug-containing particles (DCPs) with controlled size distribution and high drug loading was developed using melt granulation. This approach comprises two steps. First, melting component adsorbed particles (MAs) were prepared by mixing and heating the melting…
Read More...
Read More...
Particle movement in the spheronizer – Experimental investigations with respect to the toroidal and…
Oberservation of particle movement during wet granulation is crucial for identifying granulation mechanisms, process optimizations and troubleshooting. An example of such a process is spheronization, which is commonly used as a wet granulation technique to produce spherical, pharmaceutical pellets.…
Read More...
Read More...
Dabigatran Formulation for Oral Administration – an Evaluation
Dabigatran etexilate mesylate is a pro-drug of Dabigatran – a BSC Class II drug used as anti-coagulant in deep vein thrombosis as a direct thrombin inhibitor. Due to increasing solubility in the acidic regime, tartaric acid pellets (TAP) are used as starter beads. A processed formulation is compared…
Read More...
Read More...
Pellets 4.0 – Advanced Fluidized Bed Technologies
By Dr. Annette Grave - Glatt Pharmaceutical Services
Fluid bed processes were first developed for the chemical industry to achieve better drying efficiencies than obtained with existing technologies e. g with tray drying. Implementation of spray nozzles in the fluid bed equipment enabled…
Read More...
Read More...
The Value of Bead Coating in the Manufacturing of Amorphous Solid Dispersions: A Comparative…
Despite the fact that an amorphous solid dispersion (ASD)-coated pellet formulation offers potential advantages regarding the minimization of physical stability issues, there is still a lack of in-depth understanding of the bead coating process and its value in relation to spray drying. Therefore,…
Read More...
Read More...
Development and evaluation of extended release metformin pellets suspended in teneligliptin jelly…
During chronic treatment of diabetes mellitus, a few patients may need combination therapy with metformin hydrochloride (MH). Such combinations are available in the form of tablets. However, the size of these tablets is large and may lead to difficulty in swallowing, especially in case of geriatric…
Read More...
Read More...
Pharmatrans specific functional starter cores for improved bioavailability and dissolution
Pharmatrans Sanaq specialized range of pharmaceutical excipients and novel drug vehicles includes pellets to aid design of various types of solid dosage forms.
The range has been extended from standard types of microcrystalline cellulose, such as neutral starter cores CELLETS®, purely made of…
Read More...
Read More...